Biomerica Appoints Scott Madel As Chief Commercial Officer, Tapping Clinical Diagnostics Veteran To Lead Global Growth

Biomerica Inc., a global biomedical company focused on innovative solutions in gastroenterology, has announced the appointment of Scott Madel as Chief Commercial Officer. With more than 20 years of experience in healthcare, diagnostics, commercialization, and payor strategy, Scott will play a key role in driving the company’s commercial initiatives forward. In his new role, Scott will be responsible for expanding and accelerating the commercialization of inFoods® IBS. His focus will include building strategic partnerships, strengthening the company’s payer strategy, achieving third-party reimbursement, and scaling both domestic and international provider engagement and brand visibility.

Before joining Biomerica, Scott served as President of Boston Heart Diagnostics, where he led a successful turnaround of the organization. He introduced new cardiovascular testing technologies across various payer channels and significantly increased revenue through personalized diagnostic offerings. Earlier in his career, Scott held leadership roles including CEO of BioHealth Diagnostics and CEO of Genova Diagnostics Europe. He initially joined Genova as Vice President of Business Development and contributed to the company’s growth to over \$100 million in annual revenue. His efforts also included launching diagnostics for chronic diseases, establishing strategic partnerships in more than 45 countries, and leading the profitable expansion of a certified clinical laboratory in Europe.

Mr. Madel, stated, “I’m excited to join Biomerica and champion the growth of inFoods® IBS. This innovative solution has the potential to substantially improve the quality of life for millions of patients suffering from chronic GI conditions. I look forward to working alongside the team to bring this clinically proven breakthrough technology to practitioners and patients worldwide delivering better outcomes, improving patient experience, and reducing the cost to treat this chronic condition.”

Zack Irani, CEO of Biomerica, mentioned, “Scott’s rich commercial experience, knowledge and deep industry relationships should dramatically increase revenues from inFoods® IBS across markets. We’re confident his strategic insights will drive our domestic launch and future international business.”

Scott began his career in frontline sales roles at Novartis Pharmaceuticals and Merck, which provided him with comprehensive insight into the commercial process from the ground up. He earned a Bachelor of Science in Medical Microbiology and Immunology from the University of Wisconsin–Madison, studied at King’s College London, and is currently completing his MBA at Northeastern University. His appointment marks a strategic move by Biomerica to strengthen its market position and advance its gastroenterology product portfolio globally.